<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00237198</url>
  </required_header>
  <id_info>
    <org_study_id>CFEM345F1203</org_study_id>
    <nct_id>NCT00237198</nct_id>
  </id_info>
  <brief_title>Study of Safety and Efficacy of Letrozole Monotherapy as Second-line Endocrine Therapy in Postmenopausal Patients With Advanced Breast Cancer Who Received Previous Anti-estrogen Treatment</brief_title>
  <official_title>Study of Safety and Efficacy of Letrozole Monotherapy as Second-line Endocrine Therapy in Postmenopausal Patients With Advanced Breast Cancer Who Received Previous Anti-estrogen Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chugai Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      -  Safety and efficacy of letrozole 2.5 mg/day monotherapy as second-line endocrine therapy&#xD;
           in postmenopausal patients with advanced breast cancer who received previous&#xD;
           anti-estrogen treatment&#xD;
&#xD;
        -  To investigate changes in blood drug concentrations and blood hormone kinetics.&#xD;
&#xD;
        -  To investigate gene polymorphisms of CYP2A6, an enzyme involved in the metabolism of&#xD;
           letrozole&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety during treatment</measure>
    <time_frame>Until disease progression or appearance of unacceptable toxicity whichever comes first</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Response Rate during treatment</measure>
    <time_frame>Until disease progression or appearance of unacceptable toxicity whichever comes first</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate during treatment</measure>
    <time_frame>Until disease progression or appearance of unacceptable toxicity whichever comes first</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>from the first date of response confirmed and the last date of response confirmed</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>from the first date of response confirmed and the last date of response confirmed</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure</measure>
    <time_frame>from the date of study initiation and the date of disease progression confirmed or discontinuation other than disease progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma drug concentration from baseline, every 4 weeks until 28 weeks, at 40 weeks and at 52 weeks</measure>
    <time_frame>Baseline, 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma estrogens level</measure>
    <time_frame>baseline, 52 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Postmenopausal Women With Advanced Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Letrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <arm_group_label>Letrozole</arm_group_label>
    <other_name>FEM345</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with histologically or cytologically documented breast cancer&#xD;
&#xD;
          -  Patients with progressive breast cancer (advanced breast cancer, locoregional&#xD;
             recurrence not operative, or metastatic breast cancer)&#xD;
&#xD;
          -  Patients with hormone receptor (ER and/or PgR) positive or both unknown.&#xD;
&#xD;
          -  Postmenopausal patients between ages 20 and 79 years, inclusive&#xD;
&#xD;
          -  Patients with a history of adjuvant therapy or advanced breast cancer treated with&#xD;
             anti-estrogens&#xD;
&#xD;
          -  Patients with documented measurable or evaluable lesions.&#xD;
&#xD;
          -  Patients with sufficient organ function to evaluate the safety&#xD;
&#xD;
          -  Patients whose performance status (PS) is 0ï½ž2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with diffuse lymphangitis carcinomatosa of the lung or CNS involvement, liver&#xD;
             metastasis occupying more than one third of the liver, or inflammatory breast cancer&#xD;
&#xD;
          -  Patients with other concurrent or previous malignant disease (excluding contralateral&#xD;
             breast cancer, in situ carcinoma of cervix uteri, and adequately treated basal or&#xD;
             squamous cell carcinoma of the skin)&#xD;
&#xD;
          -  Patients in whom one of the following is the sole manifestation of disease: hilar&#xD;
             enlargement, pleural effusion and ascites&#xD;
&#xD;
          -  Patients with only blastic bone metastases or a mixed blastic and lytic bone&#xD;
             metastases at the same site and no other measurable or evaluable lesions&#xD;
&#xD;
          -  Patients with serious current disease such as uncontrolled cardiac diseases and/or&#xD;
             uncontrolled diabetes mellitus by any medications (including a historical serious&#xD;
             cardiac disease)&#xD;
&#xD;
          -  Patients with adrenal insufficiency (treated or untreated) or Cushing's syndrome&#xD;
&#xD;
          -  Patients with any of the following previous treatments&#xD;
&#xD;
               1. Chemotherapy for metastatic and/or locoregional recurrent disease&#xD;
&#xD;
               2. Previous adjuvant endocrine therapy other than ovariectomy, anti-estrogen&#xD;
                  treatment, LH-RH analogues or radiation castration&#xD;
&#xD;
               3. Previous first-line endocrine therapy (e.g., aromatase inhibitors and gastagens)&#xD;
                  for the treatment of metastatic and/or locoregional recurrent breast cancer other&#xD;
                  than anti-estrogen or LH-RH analogues treatment&#xD;
&#xD;
               4. Patients who have not recovered from toxicity caused by previous therapy&#xD;
&#xD;
               5. For patients on investigational drugs, adequate wash-out periods of at least 7&#xD;
                  days in the case of topical investigational drugs and at least 30 days in the&#xD;
                  case of systemic&#xD;
&#xD;
               6. Previous bisphosphonate therapy started within 6 months without any other&#xD;
                  measurable or evaluable lesions&#xD;
&#xD;
               7. Patients who have not stopped treatment with other anti-estrogen or anti-cancer&#xD;
                  drugs (other than bisphosphonates) before starting the trial medication&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>464-8681</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>465-0024</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Matsuyama</city>
        <state>Ehime</state>
        <zip>791-0280</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kooriyama</city>
        <state>Fukushima</state>
        <zip>963-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Maebashi</city>
        <state>Gunma</state>
        <zip>371-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kure</city>
        <state>Hiroshima</state>
        <zip>737-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>003-0804</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>063-0812</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>241-0815</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kurashiki</city>
        <state>Okayama</state>
        <zip>701-0192</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kitaadachi-gun</city>
        <state>Saitama</state>
        <zip>338-8553</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sunto-gun</city>
        <state>Shizuoka</state>
        <zip>411-8777</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-8677</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cyuo-ku</city>
        <state>Tokyo</state>
        <zip>104-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koto</city>
        <state>Tokyo</state>
        <zip>135-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>160-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>811-1395</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fukushima</city>
        <zip>960-1295</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Niigata</city>
        <zip>951-8566</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Osaka</city>
        <zip>537-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shizuoka</city>
        <zip>420-0881</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>October 9, 2005</study_first_submitted>
  <study_first_submitted_qc>October 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2005</study_first_posted>
  <last_update_submitted>February 21, 2017</last_update_submitted>
  <last_update_submitted_qc>February 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aromatase inhibitor</keyword>
  <keyword>letrozole</keyword>
  <keyword>breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

